Hand Foot Mouth Disease

• Molecular epidemiological study and mathematical modelling of Hand, foot, and mouth disease (HFMD) in primary school setting in Thailand.

Malaria vivax

• An Open Label, Non-comparative,  Multicenter Study to Assess the Pharmacokinetics, Safety and Efficacy of Tafenoquine (SB-252263, WR238605) in The Treatment of Pediatric Subjects with Plasmodium vivax Malaria.

Dengue

• Phase III, Double-Blind, Randomized, Placebo-Controlled Trial to Investigate the Efficacy, Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TDV) Administered Subcutaneously in Healthy Children Aged 4 – 16 Years Old.

• Epidemiological study of fever with rash (Zika) in Ampawa district, Samutsongkram province (pilot study)

RSV

• A Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetic/ Pharmacodynamic Relationships of Different Doses of JNJ-53718678 in Children ≥28 Days and ≤3 Years of Age With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus Infection)”

Influenza

• A Randomized, Observer-blind, Active Comparator-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-derived Quadrvalent VLP influenza Vaccine in Adults 65 Years of Age and Older

• A Phase III, Randomized, Observer-blind, Multicenter Study to Evaluate the Efficacy, Immunogenicity and Safety of Seqirus’ Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) Compared to a Non-Influenza Vaccine when Administrated in Healthy Subjects aged 6 Months through 47 Months

• A Multinational, Comparative Phase III Clinical Trial to Assess the Efficacy (Immunogenicity) and Safety of NBP607-QIV (0.5 mL) (Quadrivalent Inactivated Cell Culture-Derived Influenza Vaccine) in Children Aged 6 to 35 Months

JE vaccine

• Immunogenicity and Safety of Inactivated Vero cell derived Japanese Encephalitis Vaccine in Thai children.

The important and complete research works include:

Dengue

• Burden of dengue infection in children and adults of Bang Phae district, Ratchaburi province, Thailand (Dengue Serological Survey).

• A Phase I/II, Randomized, Observer-Blind, Multicenter Study to Evaluate Immunogenicity and Safety of Four Influenza Vaccines in Healthy Pediatric Subjects 6 to <48 Months of Age (Protocol Number: V58P16).

• Long-Term Follow-Up of Hospitalized Dengue and Safety in Thai Children Who Were Included in an Efficacy Study of a Tetravalent Dengue Vaccine (CYD57).

• Association of Host Immune Genetics and Vaccine Efficacy, and Evaluation of Immune Correlates of Risk from the First Proof of Concept Efficacy Study with a Tetravalent Dengue Vaccine) (CYD59).

• Epidemiological study of dengue infection in children in Ratchaburi Province (RAT0148).

• Safety and immunogenicity of tetravalent dengue vaccine formulations in healthy Thai children, clinical trial protocol amendment 3 version number 2.0 date 09 August 2004 (DEN06199 amendment 3).

• Dengue antibodies level and incidence of dengue infection in pre-school-aged children (Data analysis) (DEN0448).

• Socio-behavioral focus group study of community knowledge and attitudes related to the dengue fever and an up-coming dengue vaccination in Ratchaburi, Thailand.

• Study of dengue antibody in infants.

Rabies

• Evaluation of long-term-immunity against rabies in children vaccinated with Purified Chick Embryo Cell Rabies Vaccine (Rabipur) in different pre-exposure regimens and boosted after one year.

• Favirab^TM post prescription event monitoring.

• Immunogenicity and safety of PVRV postexposure vaccination in Thai children.

• Long term rabies antibody profiles in children after id and im administration of purified Vero cell rabies vaccine pre-exposure vaccination and effect of booster doses.

• Early immune response to multi-sites intramuscular injection of purified Vero cell rabies vaccine (PVRV) for rabies post-exposure treatment.

• A phase II, pilot, randomized, open-label, single-center study to evaluate immunogenicity, safety and booster response of 3 full intramuscular doses versus 3 half intramuscular dose versus 3 intradermal doses versus 2 intradermal doses of PCEC rabies vaccine (Rabipur) administered concomitantly with Japanese encephalitis vaccine as a pre-exposure regimen in 12 to 18 months old toddlers in Thailand.

Influenza

• A Phase III, Stratified, Randomized, Observer Blind, Controlled, Multicenter Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children >6 to <72 Months of Age (Protocol Number: V118_05).

JE vaccine

• The study of immunogenicity and adverse reaction of JE vaccine (liquid form) Beijing strain produced by the Government Pharmaceutical Organization of Thailand in Thai children.

Parasitic infection

• Albendazole efficacy in reducing intestinal parasites, improving nutritional, physical status and intelligence in Thai school children infected with common geohelminths.

Malaria

• A randomized comparative trial with suppositories artesunate plus mefloquine and oral artesunate plus mefloquine in uncomplicated symptomatic falciparum malaria in children in Thailand.

  Clinical trial and pharmacokinetic of artesunate suppositories in Thai children with acute uncomplicated falciparum malaria.

Other Vaccine

• Safety, tolerability and immunogenicity of the acellular pertussis vaccine combined with diphtheria and tetanus toxoid (DtaP).

• Efficacy, safety and tolerability of Tiorfan in the treatment of acute diarrhea in children.